Business
Microbot Medical® Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors
Mr. Wilson has a Track Record of Leading Product Launches and Achieving Revenue Growth in the Endovascular Devices Market BRAINTREE, Mass., Jan. 13, 2025
About this update from Microbot Medical Inc.
[{"type":"text","content":"Mr. Wilson has a Track Record of Leading Product Launches and Achieving Revenue Growth in the Endovascular Devices Market\nBRAINTREE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, is continuing its transition into a commercially focused company with the election of David J. Wilson to the Board of Directors. Mr. Wilson is a seasoned healthcare executive with a background of commercial success and revenue growth in the endovascular devices market. Mr. Wilson’s career spans over 30 years and includes broad, global leadership expertise in business strategy and operations, R&D, commercial readiness and product launches. He dedicated two decades in roles of increasing responsibility with various Johnson and Johnson (J&J) companies, including as the Worldwide President of Cordis. David held other leadership roles at J&J companies, namely Worldwide President of Mentor, Worldwide Vice President of Ethicon R&D and Vice President of Ethicon Biosurgery. Prior to his current role, David was the President of Global Plasma at Haemonetics Corporation where he led the global commercialization of a next generation plasma collection system. David is currently the CEO of InnovHeart, an Italian-based company focused on transcatheter mitral valve replacement. He is the holder of numerous medical device patents and has served as a Board member of several educational and healthcare institutions in the US. His education includes a Bachelor of Mechanical Engineering from Auburn University, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham and a Master of Business Administration from Columbia University. “As we transition to a commercially focused organization, it’s important that we continue to strengthen our leadership team by adding leaders with extensive commercial experience, specifically in the endovascular space. David’s guidance will be invaluable as we prepare for the commercial launch of LIBERTY® which we expect to take place during the second quarter of 2025,” commented Harel Gadot, Chairman, CEO and President. Mr. Wilson replaced Mr. Yossi Bornstein, a Board member since before the Company became public in 2016, whose last term as a director ended in December 2024. “We want to thank Yossi for his invaluabl...